Short Interest in Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Drops By 53.5%

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) was the recipient of a large drop in short interest in July. As of July 31st, there was short interest totaling 3,860 shares, a drop of 53.5% from the July 15th total of 8,310 shares. Based on an average daily volume of 25,979 shares, the short-interest ratio is currently 0.1 days. Approximately 0.1% of the shares of the stock are short sold.

Kiora Pharmaceuticals Stock Performance

KPRX traded down $0.04 during midday trading on Friday, hitting $2.55. The company had a trading volume of 41,172 shares, compared to its average volume of 18,071. Kiora Pharmaceuticals has a twelve month low of $1.76 and a twelve month high of $3.01. The company has a market capitalization of $11.28 million, a PE ratio of -1.02 and a beta of -0.38. The firm’s 50-day simple moving average is $2.56 and its 200-day simple moving average is $2.38.

Kiora Pharmaceuticals (NASDAQ:KPRX) last announced its earnings results on Friday, August 7th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.13.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Two Sigma Investments LP acquired a new stake in shares of Kiora Pharmaceuticals in the 3rd quarter valued at $33,000. Renaissance Technologies LLC lifted its stake in shares of Kiora Pharmaceuticals by 71.0% during the fourth quarter. Renaissance Technologies LLC now owns 21,200 shares of the company’s stock valued at $42,000 after acquiring an additional 8,800 shares during the period. Citadel Advisors LLC bought a new position in Kiora Pharmaceuticals in the third quarter valued at about $125,000. Alyeska Investment Group L.P. bought a new position in Kiora Pharmaceuticals in the fourth quarter valued at about $152,000. Finally, DRW Securities LLC increased its position in Kiora Pharmaceuticals by 199.2% in the fourth quarter. DRW Securities LLC now owns 110,282 shares of the company’s stock worth $217,000 after purchasing an additional 73,417 shares during the period. Institutional investors and hedge funds own 76.97% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised Kiora Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 14th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $10.00.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals, Inc (NASDAQ: KPRX) is a clinical-stage biotechnology company dedicated to developing innovative therapies for serious eye diseases. The company’s research efforts focus on modulating immune and neurological pathways in the eye to address conditions that currently have limited treatment options. Kiora’s approach combines small-molecule immunomodulators with advanced gene-based and optogenetic technologies to preserve and restore vision.

The company’s lead product candidate, KIO-100 (PP-001), is an intravitreal formulation designed to inhibit key inflammatory pathways implicated in non-infectious uveitis and other autoimmune ocular disorders.